Literature DB >> 17956232

Mast cells and degradation of pericellular and extracellular matrices: potential contributions to erosion, rupture and intraplaque haemorrhage of atherosclerotic plaques.

P T Kovanen1.   

Abstract

Mast cells are present in advanced human atherosclerotic plaques, where they are thought to exert multiple effects on their neighbouring cells and on the extracellular matrix of the plaque. Extensive efforts at delineating their role(s) in atherosclerotic plaques have unravelled mechanisms by which plaque mast cells may render advanced atherosclerotic plaques susceptible to erosion, rupture or intraplaque haemorrhage and so modulate their stability. In these mechanisms, the key effector molecules are mast-cell-derived neutral proteases and pro-inflammatory cytokines. These effector molecules are synthesized and stored in the cytoplasmic secretory granules of mast cells and, once the mast cells are activated to degranulate, are released into the microenvironment surrounding the activated mast cells. In the plaques, the key target cells are endothelial cells and smooth muscle cells and their pericellular matrices. In addition, the various components of the extracellular matrix of the plaques, notably collagen, are degraded when the released mast cell proteases activate matrix metalloproteinases in the plaques. By rendering the plaque susceptible to erosion, to rupture or to intraplaque haemorrhage, the mast cells may contribute to the onset of acute atherothrombotic complications of coronary atherosclerosis, such as myocardial infarction.

Entities:  

Mesh:

Year:  2007        PMID: 17956232     DOI: 10.1042/BST0350857

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  16 in total

Review 1.  Myeloid cells in atherosclerosis: initiators and decision shapers.

Authors:  Oliver Soehnlein; Christian Weber
Journal:  Semin Immunopathol       Date:  2009-02-24       Impact factor: 9.623

Review 2.  Mast cells in atherogenesis: actions and reactions.

Authors:  Petri T Kovanen
Journal:  Curr Atheroscler Rep       Date:  2009-05       Impact factor: 5.113

3.  Noninvasive Positron Emission Tomography Imaging of Coronary Arterial Inflammation.

Authors:  Amr Abdelbaky; Ahmed Tawakol
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-02-01

Review 4.  Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing.

Authors:  Jeffrey Douaiher; Julien Succar; Luca Lancerotto; Michael F Gurish; Dennis P Orgill; Matthew J Hamilton; Steven A Krilis; Richard L Stevens
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

5.  Neutrophil adhesion on endothelial cells in a novel asymmetric stenosis model: effect of wall shear stress gradients.

Authors:  Leonie Rouleau; Ian B Copland; Jean-Claude Tardif; Rosaire Mongrain; Richard L Leask
Journal:  Ann Biomed Eng       Date:  2010-04-13       Impact factor: 3.934

6.  Plasma fibrin clot properties in atopic dermatitis: links between thrombosis and atopy.

Authors:  Magdalena Nastałek; Anna Wojas-Pelc; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

Review 7.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

Review 8.  New developments in mast cell biology.

Authors:  Janet Kalesnikoff; Stephen J Galli
Journal:  Nat Immunol       Date:  2008-11       Impact factor: 25.606

9.  Inflammation in cardiovascular tissue engineering: the challenge to a promise: a minireview.

Authors:  Agneta Simionescu; Jason B Schulte; George Fercana; Dan T Simionescu
Journal:  Int J Inflam       Date:  2011-07-09

Review 10.  Functional alterations of myeloid cell subsets in hyperlipidaemia: relevance for atherosclerosis.

Authors:  Oliver Soehnlein; Maik Drechsler; Mihail Hristov; Christian Weber
Journal:  J Cell Mol Med       Date:  2009-11-09       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.